Skip to main content
    T

    TransMedics Group Inc (TMDX)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $92.21
    +0.83 (+0.91%)

    Market Cap: $3.17B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    TransMedics Group Inc (TMDX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    TransMedics Group reported revenue of $605.49M for the fiscal year ended Dec 31, 2025, up 37.1% from the year before. That year, net income was $190.29M with a net margin of 31.4%, operating cash flow was $192.84M and free cash flow was $133.59M. The quarter ended Sep 30, 2026 had revenue of $203.00M and net income of $17.07M.

    Revenue and Margins

    The operating margin was 17.9% in the fiscal year ended Dec 2025, the highest of the 4 years shown with an operating margin. Over the 9 years to Dec 2025, revenue grew from $6.21M, a compound annual rate of 66.3%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$605.49M+37.1%59.9%17.9%31.4%
    Dec 2024$441.54M+82.7%59.4%8.5%8.0%
    Dec 2023$241.62M+158.5%63.8%-11.9%-10.4%
    Dec 2022$93.46M+208.8%69.8%-33.6%-38.8%
    Dec 2021$30.26M+18.0%69.9%-130.3%-146.1%
    Dec 2020$25.64M+8.6%64.9%-102.9%-112.1%
    Dec 2019$23.60M+81.3%58.7%-125.4%-142.1%
    Dec 2018$13.02M+69.4%44.1%-155.5%-182.5%
    Dec 2017$7.68M+23.8%27.8%-265.8%-271.0%
    Dec 2016$6.21MN/A12.3%-370.2%-387.6%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income rose 436.6% from the year before. In the quarter ended Sep 2026, net income fell 29.8% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$605.49M$441.54M$241.62M$93.46M$30.26M$25.64M$23.60M$13.02M$7.68M$6.21M
    Cost of revenue$242.69M$179.46M$87.53M$28.19M$9.10M$9.00M$9.74M$7.28M$5.55M$5.44M
    Gross profit$362.81M$262.08M$154.09M$65.27M$21.16M$16.64M$13.86M$5.73M$2.14M$766.00K
    Research and development$69.06M$55.97M$63.27M$26.81M$22.30M$18.83M$19.87M$13.66M$14.96M$15.64M
    Operating income$108.58M$37.50M-$28.73M-$31.44M-$39.43M-$26.38M-$29.60M-$20.24M-$20.43M-$22.99M
    Net income$190.29M$35.46M-$25.03M-$36.23M-$44.22M-$28.75M-$33.55M-$23.76M-$20.82M-$24.07M
    EBITDA$148.49M$69.95M-$7.70M-$28.58M-$37.13M-$22.52M-$28.14M-$20.23M-$19.09M-$22.66M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$203.00M$189.95M$173.93M$160.76M$143.82M$157.37M$143.54M$121.62M$108.76M$114.31M$96.85M$81.17M
    Gross profit$118.66M$113.20M$101.16M$93.41M$84.58M$96.59M$88.23M$72.01M$60.84M$69.26M$59.96M$47.92M
    Operating income$28.14M$23.74M$13.30M$21.27M$23.30M$36.57M$27.44M$8.64M$3.92M$12.51M$12.42M$2.60M
    Net income$17.07M$14.68M$7.32M$105.38M$24.32M$34.91M$25.68M$6.86M$4.22M$12.19M$12.20M$4.03M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $512.39M exceeded cash and equivalents by $24.02M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$1.07B$804.08M$706.05M$277.15M$134.89M$152.03M$105.30M$42.16M$37.00M$58.10M
    Current assets$637.78M$497.22M$510.65M$252.29M$118.70M$146.77M$100.00M$34.79M$34.04M$55.86M
    Cash and equivalents$488.37M$336.65M$394.81M$201.18M$25.58M$24.58M$20.09M$20.24M$11.94M$9.84M
    Total liabilities$595.27M$575.47M$568.85M$89.77M$67.04M$48.13M$50.65M$47.88M$205.72M$19.32M
    Short-term debt$10.00M$0$2.04M$1.44M$8.60MN/AN/AN/A$1.80MN/A
    Long-term debt$502.39M$509.31M$506.20M$58.70M$35.20M$34.66M$34.15M$33.67M$6.85M$8.41M
    Shareholder equity$473.10M$228.60M$137.20M$187.38M$67.85M$103.89M$54.65M-$192.24M-$168.72M$38.79M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$1.52B$1.46B$1.43B$1.07B$946.03M$890.52M$837.53M$804.08M$785.57M$758.58M$723.83M$706.05M
    Total liabilities$967.23M$946.34M$940.81M$595.27M$590.83M$572.42M$571.22M$575.47M$575.65M$568.68M$564.36M$568.85M
    Cash and equivalents$492.96M$472.68M$461.74M$488.37M$466.17M$400.57M$310.14M$336.65M$330.09M$362.75M$350.22M$394.81M
    Shareholder equity$550.71M$518.05M$494.01M$473.10M$355.20M$318.10M$266.31M$228.60M$209.92M$189.89M$159.47M$137.20M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 69.3% of operating cash flow.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$192.84M$48.80M-$13.03M-$45.82M-$28.86M-$30.27M-$32.29M-$25.98M-$23.10M-$24.11M
    Capital expenditures$59.25M$129.74M$151.85M$11.91M$3.52M$455.00K$165.00K$418.00K$263.00K$1.48M
    Free cash flow$133.59M-$80.94M-$164.88M-$57.72M-$32.38M-$30.72M-$32.45M-$26.40M-$23.36M-$25.59M
    Dividends paidN/AN/A$51.12MN/AN/A$357.00KN/AN/AN/AN/A
    Share repurchasesN/AN/AN/A$0$0$0$4.85MN/AN/AN/A
    Investing cash flow-$59.25M-$129.30M-$193.95M$54.51M$29.27M-$41.60M-$60.50M$12.31M$24.86M-$39.67M
    Financing cash flow$16.86M$22.87M$400.42M$167.93M$1.39M$75.55M$92.72M$22.06M$3.00K$63.54M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$36.00M$17.31M$24.53M$34.51M$69.57M$91.61M-$2.85M$19.66M$6.86M$25.72M-$3.44M$8.30M
    Capital expenditures$8.40M$7.09M$36.66M$15.51M$7.62M$9.07M$27.04M$13.61M$48.20M$23.76M$44.17M$41.82M
    Free cash flow$27.60M$10.22M-$12.12M$19.00M$61.95M$82.53M-$29.89M$6.06M-$41.35M$1.96M-$47.61M-$33.51M
    Last 12 quarters

    Frequently Asked Questions About TMDX

    What is TransMedics Group's annual revenue?

    TransMedics Group reported revenue of $605.49M for the fiscal year ended Dec 31, 2025.

    How fast is TransMedics Group's revenue growing?

    Revenue was up 37.1% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 86.4%.

    Is TransMedics Group profitable?

    Yes. TransMedics Group reported net income of $190.29M for the fiscal year ended Dec 31, 2025, with a net margin of 31.4%.

    How much free cash flow does TMDX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $192.84M minus capital expenditures of $59.25M produced free cash flow of $133.59M.

    How much debt does TransMedics Group have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $502.39M, short-term debt of $10.00M and cash and equivalents of $488.37M.